Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study

Abstract Weight gain is a frequent and severe adverse reaction in patients taking antipsychotics. The objective was to further investigate in a natural setting influential risk factors associated with clinically significant weight gain. An observational follow-up study was conducted. Patients when i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalia Jimeno, Veronica Velasco-Gonzalez, Inmaculada Fierro, Mercedes Duran, Alfonso Carvajal
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7e3f85aff39742e1ac2668165a22cf09
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e3f85aff39742e1ac2668165a22cf09
record_format	dspace
spelling	oai:doaj.org-article:7e3f85aff39742e1ac2668165a22cf092021-12-02T16:06:41ZAssociation of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study10.1038/s41598-021-94700-92045-2322https://doaj.org/article/7e3f85aff39742e1ac2668165a22cf092021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94700-9https://doaj.org/toc/2045-2322Abstract Weight gain is a frequent and severe adverse reaction in patients taking antipsychotics. The objective was to further investigate in a natural setting influential risk factors associated with clinically significant weight gain. An observational follow-up study was conducted. Patients when initiating treatment with whatever antipsychotic were included; a structured questionnaire was applied at baseline, 3 and 6 months later; a blood sample was obtained. In a nested case–control approach, patients with an increase ≥ 7% of their initial weight were considered as cases, the remaining, as controls. The results showed that, out of 185 patients, 137 completed the 6-month follow-up (cases, 38; controls, 99). Weight gain gradually and significantly increased in cases (baseline, 65.0 kg; 6 months, 74.0 kg) but not in controls (65.6 kg and 65.8 kg, respectively). Age (adjusted OR = 0.97, 95% CI = 0.96–0.99, p = 0.004), olanzapine (adjusted OR = 2.98, 95% CI = 1.13–7.80, p = 0.027) and quetiapine (adjusted OR = 0.25, 95% = 0.07–0.92, p = 0.037) significantly associated with weight gain. An association was also found for the CNR1 (rs1049353) and INSIG2 (rs7566605) polymorphisms. In conclusion, an increased risk of antipsychotics-induced weight gain was observed for younger age and olanzapine, and a relative lower risk for quetiapine. A potential role of CNR1 rs1049353 and INSIG2 rs7566605 polymorphisms is suggested.Natalia JimenoVeronica Velasco-GonzalezInmaculada FierroMercedes DuranAlfonso CarvajalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Natalia Jimeno Veronica Velasco-Gonzalez Inmaculada Fierro Mercedes Duran Alfonso Carvajal Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
description	Abstract Weight gain is a frequent and severe adverse reaction in patients taking antipsychotics. The objective was to further investigate in a natural setting influential risk factors associated with clinically significant weight gain. An observational follow-up study was conducted. Patients when initiating treatment with whatever antipsychotic were included; a structured questionnaire was applied at baseline, 3 and 6 months later; a blood sample was obtained. In a nested case–control approach, patients with an increase ≥ 7% of their initial weight were considered as cases, the remaining, as controls. The results showed that, out of 185 patients, 137 completed the 6-month follow-up (cases, 38; controls, 99). Weight gain gradually and significantly increased in cases (baseline, 65.0 kg; 6 months, 74.0 kg) but not in controls (65.6 kg and 65.8 kg, respectively). Age (adjusted OR = 0.97, 95% CI = 0.96–0.99, p = 0.004), olanzapine (adjusted OR = 2.98, 95% CI = 1.13–7.80, p = 0.027) and quetiapine (adjusted OR = 0.25, 95% = 0.07–0.92, p = 0.037) significantly associated with weight gain. An association was also found for the CNR1 (rs1049353) and INSIG2 (rs7566605) polymorphisms. In conclusion, an increased risk of antipsychotics-induced weight gain was observed for younger age and olanzapine, and a relative lower risk for quetiapine. A potential role of CNR1 rs1049353 and INSIG2 rs7566605 polymorphisms is suggested.
format	article
author	Natalia Jimeno Veronica Velasco-Gonzalez Inmaculada Fierro Mercedes Duran Alfonso Carvajal
author_facet	Natalia Jimeno Veronica Velasco-Gonzalez Inmaculada Fierro Mercedes Duran Alfonso Carvajal
author_sort	Natalia Jimeno
title	Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
title_short	Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
title_full	Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
title_fullStr	Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
title_full_unstemmed	Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
title_sort	association of cnr1 and insig2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7e3f85aff39742e1ac2668165a22cf09
work_keys_str_mv	AT nataliajimeno associationofcnr1andinsig2polymorphismswithantipsychoticsinducedweightgainaprospectivenestedcasecontrolstudy AT veronicavelascogonzalez associationofcnr1andinsig2polymorphismswithantipsychoticsinducedweightgainaprospectivenestedcasecontrolstudy AT inmaculadafierro associationofcnr1andinsig2polymorphismswithantipsychoticsinducedweightgainaprospectivenestedcasecontrolstudy AT mercedesduran associationofcnr1andinsig2polymorphismswithantipsychoticsinducedweightgainaprospectivenestedcasecontrolstudy AT alfonsocarvajal associationofcnr1andinsig2polymorphismswithantipsychoticsinducedweightgainaprospectivenestedcasecontrolstudy
_version_	1718384909859422208

Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study

Ejemplares similares